Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium animalis subsp. lactis BL-99
- Development stage
- Unknown
- Lead developer
- Yili Group
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium animalis subsp. lactis BL-99 is a patented probiotic strain originally isolated from the feces of a healthy two-year-old Chinese infant[1][6]. It is a non-pathogenic, gastric acid and intestine juice-resistant bacterium that has been shown to modulate intestinal inflammation and promote intestinal function in preclinical models[4][6]. Clinical studies demonstrate its efficacy in alleviating symptoms of functional dyspepsia (FD) by altering the gut microbiome composition, increasing short-chain fatty acid (SCFA)-producing bacteria, and improving gastrointestinal health[8][10]. The strain also supports immune health by enhancing macrophage phagocytic activity and antibody production in animal models[4][7]. It is generally recognized as safe (GRAS), with no dose-dependent toxicity or mutagenicity observed in preclinical safety studies[6][7].
- Brand names
- NC Probiotic BL-99
- Other names
- bifidobacterium lactis BL-99B. lactis BL-99bifidobacterium animalis ssp. lactis BL-99
Beyond the preview
Go deeper on bifidobacterium animalis subsp. lactis BL-99.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium animalis subsp. lactis BL-99.